Ampakines

RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference

Retrieved on: 
Tuesday, June 8, 2021
AMPA receptor positive allosteric modulators, Ampakines, Stimulants, Drugs, CX717, Enones, Morpholines, RespireRx, Ampakine, Pharmaceutical industry in India, Anticonvulsant, OTC Markets Group

Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:

Key Points: 
  • Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:
    Access China Biotech 2021 Digital (June 9-14, 2021)
    The Access China Biotech Forumis a quarterly corporate access event series between China and Western biopharma.
  • We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.
  • From our AMPAkine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
  • At present, the major pharmacotherapies available for ADHD are made up of two types of drugs.

RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, AMPA receptor positive allosteric modulators, Ampakines, Neuroscience, Anatomy, Ampakine, Peripheral nervous system, CX717, Nerve

At 4 and 14 days following C2 cervical spinal hemi-section injury, rats were given single, low dose (5 mg/kg) intravenous injections of CX717, CX1739 or vehicle.

Key Points: 
  • At 4 and 14 days following C2 cervical spinal hemi-section injury, rats were given single, low dose (5 mg/kg) intravenous injections of CX717, CX1739 or vehicle.
  • At 4-days following injury, both AMPAkines increased diaphragm motor nerve activity (EMG) ipsilateral to the injured side during both the baseline breathing and the acute respiratory challenge.
  • These animal models of motor nerve function following SCI support proof of concept for a new treatment paradigm using AMPAkines to improve motor functions in patients with SCI.\xe2\x80\x9d\nDr.
  • At the same time, we are planning a clinical trial program focused on developing AMPAkines for the restoration of certain motor functions in patients with SCI.

RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs

Retrieved on: 
Thursday, April 22, 2021
AMPA receptor positive allosteric modulators, Ampakines, CX717, Enones, Morpholines, Stimulants, RespireRx

Authors also include Roc Cerne1,2,3,4, Arnold Lippa5, Michael Poe8, Jodi L. Smith1, Xiaoming Jin4, Xingjie Ping4 and Lalit K. Golani6.

Key Points: 
  • Authors also include Roc Cerne1,2,3,4, Arnold Lippa5, Michael Poe8, Jodi L. Smith1, Xiaoming Jin4, Xingjie Ping4 and Lalit K. Golani6.
  • KRM-II-81 is the latest GABAkine to begin development in IND-enabling toxicology investigations as a joint program of RespireRx and the University of Wisconsin-Milwaukee.
  • It is a clear recognition of the significant advancements we are making in our GABAkine programs.
  • Using rodents that have received spinal hemi-sections, CX717 was observed to increase motor nerve activity bilaterally.

RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences

Retrieved on: 
Friday, January 8, 2021
Psychoactive drugs, AMPA receptor positive allosteric modulators, Ampakines, CX717, Enones, Morpholines, Stimulants, Ampakine, Opioid, Epilepsy, Cannabis, Anticonvulsant

From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.

Key Points: 
  • From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
  • Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
  • Epilepsy is a chronic and highly prevalent neurological disorder that affects millions of people world-wide.
  • We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.

RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, October 6, 2020
Ampakine, Ampakines

According to Dr. Fuller, Autonomic and cardiovascular dysfunctions are of paramount concern in persons with spinal cord injury.

Key Points: 
  • According to Dr. Fuller, Autonomic and cardiovascular dysfunctions are of paramount concern in persons with spinal cord injury.
  • Our data shows that ampakines very effectively stimulate neural drive to the diaphragm after spinal cord injury.
  • Ampakines may, therefore, be of use in the treatment of spinally damaged patients, particularly during rehabilitation.
  • The research results from Dr. Fullers laboratory add considerable support for our intention to translationally extend this work to human clinical trials.

RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications

Retrieved on: 
Wednesday, February 5, 2020
AMPA receptor positive allosteric modulators, Ampakines, Ampakine, RespireRx, Cannabinoid, CX717, Neuropsychology, Chemistry

Provisional Patent Application further disclosing novel dosage and controlled release compositions and methods of use for cannabinoids, alone or in combination, including with non-cannabinoid molecules.

Key Points: 
  • Provisional Patent Application further disclosing novel dosage and controlled release compositions and methods of use for cannabinoids, alone or in combination, including with non-cannabinoid molecules.
  • Additional claims include cannabinoid compositions and methods for treating cannabinoid-sensitive disorders, including sleep apnea, pain, glaucoma, muscle spasms, anorexia and other conditions.
  • We believe that our patent priority relating back to 2010 predates the efforts of others seeking to develop low-dose or extended release formulations of cannabinoids.
  • RespireRx owns certain composition of matter and use patents and patent applications with respect to ampakines CX1739, CX717 and other ampakines.